The Journal of clinical investigation · 2022
The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Kyung Mi, Kim Jeong Jin, Yoo Jihye, Kim Ku Sul, Gu Youngeun, Eom John, Jeong Haengdueng, Kim Kyungeun, Nam Ki Taek, Park Young Soo, Chung Joon-Yong, Seo Jun-Young
Аннотация
OBJECTIVE: Delirium is a precursor and risk factor for dementia, emphasizing the urgency of effective prevention and management strategies in older adults with type 2 diabetes (T2D). Identifying long-term, safe, and effective medications to prevent diabetes-related delirium is crucial because of its significant impact on this population. This study aimed to evaluate the protective effects of metformin against delirium in older adults with T2D, using a competing risk analysis of death to provide a more accurate assessment.
RESEARCH DESIGN AND METHODS: Metformin users were compared with a cohort of nonusers. Multivariable Cox regression and Fine and Gray methods were used to assess the risk of delirium and mortality.
RESULTS: Our study included 66,568 metformin users and 66,568 nonusers, matched by propensity score. The use of metformin was associated with a significantly lower risk of delirium, with adjusted hazard ratios ranging from 0.77 to 0.81. A dose-response relationship was observed, indicating that higher cumulative and daily doses of metformin were associated with greater reductions in delirium risk.
CONCLUSIONS: Metformin use is associated with a reduced risk of delirium in older adults with T2D, with higher doses offering greater protection.
RESEARCH DESIGN AND METHODS: Metformin users were compared with a cohort of nonusers. Multivariable Cox regression and Fine and Gray methods were used to assess the risk of delirium and mortality.
RESULTS: Our study included 66,568 metformin users and 66,568 nonusers, matched by propensity score. The use of metformin was associated with a significantly lower risk of delirium, with adjusted hazard ratios ranging from 0.77 to 0.81. A dose-response relationship was observed, indicating that higher cumulative and daily doses of metformin were associated with greater reductions in delirium risk.
CONCLUSIONS: Metformin use is associated with a reduced risk of delirium in older adults with T2D, with higher doses offering greater protection.